Overview

4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective than observation alone in treating bladder cancer. PURPOSE: This randomized phase III trial is studying combination chemotherapy to see how well it works compared to observation alone in treating patients with bladder cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
National Cancer Institute (NCI)
NCIC Clinical Trials Group
University of Southern California
Treatments:
Cisplatin
Doxorubicin
Liposomal doxorubicin
Methotrexate
Vinblastine